Antibody‐based treatments in HNSCC, such as cetuximab (epidermal growth factor receptor; EGFR monoclonal antibody) or pembrolizumab (CD274; also known as PD‐L1 monoclonal antibody) are approved, but mostly in the recurrent/metastatic disease. Here, CD274 is linked to metastatic neoplasm.